after providing informed consent, you receive a study identification number.

your demographic information (age, sex, race) and medical history are recorded.

clinical characteristics of your kidney disease are measured, including blood tests for serum creatinine and calculation of eGFR (estimated glomerular filtration rate).

protein in the urine is measured and expressed as the urine protein‑to‑creatinine ratio (UPCR).

a kidney biopsy may be performed to evaluate disease activity and complement component C3c staining.

any prior or current treatments for c3g or ic‑mpgn are documented.

you begin receiving pegcetacoplan as a 308.6 mg subcutaneous injection (solution for infusion).

the medication is administered at regular intervals as directed by your physician; the exact schedule is individualized.

treatment continues for the duration of the study unless a dose change, switch, or discontinuation is required.

follow‑up visits are scheduled at 1 month, 3 months, 6 months, 12 months, and then every 6 months.

at each visit, the following are performed:

– measurement of UPCR to assess proteinuria, aiming for a value of less than 1 g/g.

– repeat blood tests to calculate eGFR and monitor other laboratory parameters.

– assessment of safety, including monitoring for serious infections, malignancies, and acute kidney injury.

– completion of patient‑reported outcome questionnaires such as the FACIT‑Fatigue and WPAI scales.

the study tracks whether you achieve a reduction of at least 50 % in proteinuria and whether UPCR falls below thresholds of 1 g/g, 0.5 g/g (adults), or 0.2 g/g (children).

changes in kidney function (eGFR) are recorded at each visit to detect sustained doubling of serum creatinine or progression to end‑stage kidney disease.

any new need for dialysis, kidney transplant, or death related to kidney failure is documented.

if your physician determines a dose change is necessary, the new dose and reason are recorded in the study database.

should you switch from pegcetacoplan to another complement inhibitor such as iptacopan, additional assessments are performed at 2 weeks, 1 month, 3 months, 6 months, 12 months, and every 6 months thereafter.

if pegcetacoplan is discontinued or restarted, the same laboratory and clinical evaluations are repeated at the same intervals as during continuous therapy.

biomarker levels, kidney biopsy findings, and patient‑reported outcomes are compared to the most recent measurements before the change.

the study concludes on the estimated end date of 30 june 2032 or when you stop treatment, whichever occurs first.

final assessments include the last set of laboratory tests, UPCR and eGFR measurements, and completion of the outcome questionnaires.